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Background: Hypoplastic Left Heart Syndrome (HLHS) is a severe congenital heart
defect (CHD) characterised by the underdevelopment of the left side of the heart with
varying levels of hypoplasia of the left atrium, mitral valve, left ventricle, aortic valve and
aortic arch. In the UK, age 12 survival for cases born between 1991 and 1993 was
21%. UK survival estimates corresponding to cases born between 2000 and 2015 were
improved at 56%, but survival was examined up to age five only. Contemporary long-term
survival estimates play a crucial role in counselling parents following diagnosis. The aim
of this study was to report survival estimates up to age 15 for children born with HLHS
or hypoplastic left ventricle with additional CHD in England and Wales between 1998
and 2012.
Methods: Cases of HLHS notified to four congenital anomaly registers in England and
Wales during 1998–2012, matched to Office for National Statistics mortality information,
were included. Kaplan-Meier survival estimates to age 15 were reported. Cox regression
models were fitted to examine risk factors for mortality.
Results: There were 244 cases of HLHS and 99 cases of hypoplastic left ventricle
co-occurring with other CHD, with traced survival status. Kaplan-Meier survival estimates
for HLHS were 84.4% at age 1 week, 76.2% at 1 month, 63.5% at age 1 year, 58.6%
at age 5 years, 54.6% at age 10 years, and 32.6% to age 15 years. The Kaplan-Meier
survival estimates for cases of hypoplastic left ventricle co-occurring with additional CHD
were 90.9% at age 1 week, 84.9% at 1 month, 73.7% at age 1 year, 67.7% to age 5
years, 59.2% to age 10 years, and 40.3% to age 15 years. Preterm birth (p = 0.007),
low birth weight (p = 0.005), and female sex (p = 0.01) were associated with mortality.
Conclusions: We have shown that prognosis associated with HLHS in the twenty
first century exceeds that of many previous population-based studies, likely due to
improvements in intensive care technologies and advances in surgical techniques over
the last few decades.
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INTRODUCTION
Hypoplastic Left Heart Syndrome (HLHS) is a severe congenital
heart defect (CHD) characterised by the underdevelopment of
the left side of the heart with varying levels of hypoplasia of the
left atrium, mitral valve, left ventricle, aortic valve and aortic arch
(1). Survival was not possible until the 1980s when the Norwood
procedure was introduced (2, 3). Since then, improvements
in antenatal screening, preoperative management, resuscitation,
and surgical techniques such as right ventricle-to-pulmonary
artery conduits and the hybrid procedure for neonates too
unstable (e.g., very preterm or with other comorbidities) to
undergo the Norwood procedure, have further improved the
prognosis for HLHS patients (4, 5). However, the impact of right
ventricle-to-pulmonary artery conduits and the hybrid procedure
on longer term prognosis remains under debate (6). While not
the standard approach, survival in children and adults with
HLHS may also have improved due to increased frequency and
improved survival associated with heart transplants (7).
Today the standard treatment for individuals with HLHS
is to undergo the Norwood stage I procedure (reconstruction
of the left track and modified Blalock Taussig shunt or Sano
technique) within the first 2 weeks of life, the Norwood stage
II procedure (Hemi fontan, Glenn, or partial cavo-pulmonary
bypass) procedure between 4 and 6 months of age and finally
the Norwood stage III (Fontan final phase, full cavo-pulmonary
bypass) procedure between 18 months and 4 years of age (8).
According to the UK’s National CHD audit, 30 day post-operative
survival for the Norwood, Glenn and Fontan procedures exceeds
90% (9). However, when they occur with a hypoplastic left
ventricle, other forms of CHD such as atrioventricular septal
defect (AVSD), common arterial trunk (CAT), and double outlet
right ventricle (DORV) may also be surgically treated with the
Fontan procedure, but not necessarily after a Norwood stage
I surgery as is the case for HLHS (10, 11). These forms of
CHD with a hypoplastic left ventricle, often known as functional
univentricular hearts, have better prognosis than HLHS and
so the post-surgical survival rates for HLHS specifically is
likely to be lower (12). A recent UK study reported 5 year
survival for cases of HLHS born between 2000 and 2015 was
56.3%, although this study did not ascertain those who did
not undergo any interventional treatment (13). Outside of
the UK, recent age five survival rates range between 18.8%
in New Zealand to 72% in Denmark (14, 15). Longer-term
estimates of survival from birth are important for clinicians
counselling parents when HLHS is diagnosed prenatally, as they
may aid decision making regarding continuation of pregnancy.
Given that individuals with palliated CHD will require follow-
up throughout their lives, contemporary survival estimates are
also important for commissioners whose role is to ensure
services are in place for the growing population of adults
with CHD.
The primary aim of this study was to report contemporary
survival estimates up to age 15 for children born with HLHS or
hypoplastic left ventricle in addition to other CHD subtypes in




The British and Irish Network of Congenital Anomaly Research
Database (BINOCARD) was a collaborative network of regional
population-based congenital anomaly registers (16), which was
superseded in England by a national system, the National
Congenital Anomaly and Rare Diseases Registration Service
(NCARDRS) in 2015 (17). Each regional register prospectively
collected data on congenital anomalies occurring in the
pregnancies of women residing in their geographically defined
populations (Figure 1). Data were obtained from three registers
in England and the register for Wales, covering ∼28% of
the birth population of England and Wales. The Northern
Congenital Abnormality Survey (NorCAS), established in 1985,
covered 32,000 births per year in the North East of England
and North Cumbria; the East Midlands and South Yorkshire
Congenital Anomaly Register (EMSYCAR), established in 1997
covered 74,000 births per year; the South West Congenital
Anomaly Register (SWCAR), established in 2002, covered
50,000 births per year in South West England; and the
Congenital Anomaly Register and Information Service (CARIS),
established in 1998, covers 35,000 births per year in Wales.
Each register recorded up to eight congenital anomalies for
each case. Anomalies were coded using the WHO International
Classification of Disease (ICD) version ten, consistent with the
FIGURE 1 | Map showing the area covered by the congenital anomaly
registers.
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European Surveillance of Congenital Anomalies (EUROCAT)
guidelines (18). To ensure a high case ascertainment, congenital
anomalies were notified to each register from a variety of sources
including prenatal ultrasound departments, foetal medicine
units, cytogenetic laboratories, regional cardiology centres,
pathology departments, and paediatric surgery departments.
CHD diagnoses were confirmed at surgery, by echocardiography
or cardiac catheterisation, or at post-mortem.
The register data were linked to death registrations via
NHS Digital in December 2017, using the “fuzzy matching” of
infant name, sex, date of birth, and postcode at delivery. These
identifier variables were removed or pseudo-anonymised (e.g.,
date of birth was replaced with year of birth only) following
the linkage before the data were accessed by the researcher
(KEB). While NHS Digital were able to provide the exact age of
cases resulting in mortality, it was not possible to provide the
exact age at case censorship for survivors as this would have
allowed date of birth to be identified by the researcher (due
to the linkage date being known). Therefore, age at censorship
was estimated by subtracting the number of days between the
midpoint of year of birth and December 2017. For each case with
an English postcode at birth, NHS Digital assigned the English
Index of Multiple Deprivation (IMD) score and rank. IMD is
a measure of area-level socioeconomic deprivation calculated
from income, employment, health, education, access to services,
social environment, housing stress, living environment and crime
(19, 20). IMD 2004, 2007, 2010 were used according to the year
of birth of the case. It was not possible for NHS Digital to provide
the Welsh IMD and so analysis of IMD was restricted to cases
notified to the English registers only (80.8% of cases).
England and Wales population survival estimates at ages 1
month and 1 year were taken from the Office for National
Statistics’ online vital statistics for comparison with cases of
HLHS and hypoplastic left ventricle with additional CHD (21).
Case Inclusion
Cases coded as hypoplastic left heart (ICD 10: Q234) that were
live born during 1st January 1998–31st December 2012 were
included. The EUROCAT uses the same ICD 10 code (Q234)
to describe both HLHS and severe hypoplastic left ventricle co-
occurring with other CHD subtypes such as AVSD, CAT, and
DORV (18). Given that these two forms of CHD are likely to
have different survival rates, they were classed as two separate
groups. HLHS was defined as cases coded with ICD Q234 but
no other CHD codes except for those that commonly occur as
part of HLHS: aortic valve stenosis/ atresia, mitral valve atresia/
stenosis, mitral regurgitation, aortic regurgitation, patent ductus
arteriosus, atrial septal defect, and coarctation of aorta. We
defined the remainder of cases as hypoplastic left ventricle with
additional CHD, i.e., those cases coded as ICD Q234 in addition
to any other CHD subtypes (Q20–26), excluding those listed
above. Cases that occurred with extra-cardiac anomalies (ECA’s,
i.e., chromosomal anomalies or structural congenital anomalies
of another organ system) or that occurred with additional
CHD subtypes, were included. Twenty-eight (7.5%) cases were
untraced, and these were excluded following descriptive statistics.
Ethical Approval
The BINOCARD has approval from the Confidentiality Advisory
Group of the Health Research Authority (PIAG 2-08I/2012),
to hold data without consent and ethics committee approval
(09/H0405/48) to undertake studies involving their data. The
data linkage aspect of this study was given a favourable ethical
opinion by the Newcastle & North Tyneside 2 Local Research
Ethics Committee (13/NE/0188) and the Confidentiality
Advisory Group of theHealth Research Authority [5-08(b) 2013].
Statistical Analysis
The associations between untraced survival status and
demographic (categorical) variables were examined using
χ
2 tests of association or Fisher’s exact tests. Kaplan-Meier
survival estimates were estimated at ages 1 week, 1 month, 1, 5,
10, and 15 years and according to period of birth (categorised as
1998–2005 and 2006–2012). Survival estimates were not reported
(numerically or graphically) where the number of cases at risk
was <5, given that this can produce unstable estimates.
Hazard ratios (HRs) were estimated using univariable
Cox regression models for the following predictors: extra-
cardiac anomalies [none (i.e., isolated CHD), structural (e.g.,
digestive system congenital anomalies), chromosomal (e.g.,
Down syndrome)], maternal age at delivery (<20, 20–34, ≥35
years), birth weight (low: <2,500 g, average: 2,500–3,999 g, high:
≥4,000 g), gestational age at birth (preterm: <37 weeks, term:
37–41 weeks, post-term ≥42 weeks), infant sex (male, female)
and IMD at birth [quintile 1 (most deprived), quintile 2, quintile
3 quintile 4, quintile 5 (least deprived)], plurality (singleton
or multiple).
The proportional hazards assumption was checked using log-
log plots, Schoenfield residulas, and by comparing hazard ratios
for different categorisations of survival time. P < 0.05 was
considered statistically significant and analyses were performed
in Stata 14.
RESULTS
There were 371 live born cases included in the study, giving a live
birth prevalence of 1.5 (1.4, 1.7) per 10,000 live births. Survival
status was traced for 343 (92.5%) cases. Untraced cases weremore
common in cases born earlier in the study period (p< 0.001) and
in cases born with a low or high birth weight (p = 0.002). The
proportion of traced cases also varied by register (p= 0.001), with
82.5% of CARIS cases traced up to 100% of SWCAR cases. There
was no association between traced status and gestational age at
delivery (p= 0.17), maternal age at delivery (p= 0.35), infant sex
(p = 0.90), plurality (p = 0.14), ECAs (p = 0.45), or IMD (P =
0.48). The 28 untraced cases were excluded from further analysis.
Case Characteristics
There were 244 cases defined as HLHS and 99 defined as
hypoplastic left ventricle with additional CHD. Cases of HLHS
were most commonly: isolated CHD (n = 220, 90.2%), born at
>37 weeks gestation (n = 195, 83.7% of cases with available
gestational age), with average birth weight (n = 171, 71.8%), to
mothers aged 20-34 (n = 160, 69.0%), of male sex (n = 140,
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TABLE 1 | Birth characteristics of cases of HLHS and hypoplastic left ventricle
with additional CHD.
Risk factors All cases






n (% of 99)
Register
CARIS 66 (19.2) 57 (23.4) 9 (9.1)
EMSYCAR 162 (47.2) 103 (42.2) 59 (59.6)
NorCAS 50 (14.6) 41 (16.8) 9 (9.1)
SWCAR 65 (19) 43 (17.6) 22 (22.2)
Year of birth
1998–2005 137 (39.9) 109 (44.7) 28 (28.3)
2006–2012 234 (68.2) 157 (64.3) 77 (77.8)
Gestational age
Preterm (<37 weeks) 50 (14.6) 38 (15.6) 12 (12.1)
Term/Post-term (≥37
weeks)
280 (81.6) 195 (79.9) 85 (85.9)
Missing 13 (3.8) 11 (4.5) 2 (2.0)
Birth weight
Low (<2,500 g) 63 (18.4) 41 (16.8) 22 (22.2)
Average
(2,500–3,999 g)
240 (70) 171 (70.1) 69 (69.7)
High (≥4000g) 32 (9.3) 26 (10.7) 6 (6.1)
Missing
Maternal age
<20 44 (12.8) 29 (11.9) 15 (15.2)
20–34 225 (65.6) 160 (65.6) 65 (65.7)
≥35 61 (17.8) 43 (17.6) 18 (18.2)
Missing 44 (12.8) 29 (11.9) 15 (15.2)
Sex
Female 139 (40.5) 104 (42.6) 35 (35.4)
Male 204 (59.5) 140 (57.4) 64 (64.6)
Socioeconomic deprivation (IMD)
Least deprived Q1 38 (11.1) 27 (11.1) 11 (11.1)
Q2 38 (11.1) 25 (10.2) 13 (13.1)
Q3 43 (12.5) 21 (8.6) 22 (22.2)
Q4 61 (17.8) 46 (18.9) 15 (15.2)
Most deprived Q5 92 (26.8) 64 (26.2) 28 (28.3)
Missing 71 (20.7) 61 (25.0) 10 (10.1)
Extra cardiac anomalies
Isolated CHD 297 (86.6) 220 (90.2) 77 (77.8)
Structural ECA 27 (7.9) 12 (4.9) 15 (15.2)
Chromosomal ECA 19 (5.5) 12 (4.9) 7 (7.1)
HLHS, Hypoplastic Left Heart Syndrome; ECA, Extra Cardiac Anomaly, IMD, Index of
Multiple Deprivation.
57.3%) and to mothers residing in the most deprived areas (IMD
quintile 5: n= 35, 30.2%) (Table 1).
Cases of hypoplastic left ventricle co-occurring with
additional CHD, were more commonly: isolated CHD (n =
77, 77.8%), born at >37 weeks gestation (n = 85, 87.6%), of
average birth weight (n = 69, 71.1%), to mothers aged 20–34
(n = 65, 66.3%), of male sex (n = 64, 64.6%) and to mothers
TABLE 2 | Kaplan-Meier survival estimates for HLHS and hypoplastic left ventricle









Survival % (95% CI)
1 week 86.3 (82.2, 89.5) 84.4 (79.2, 88.4) 90.9 (83.3, 95.2)
1 month 78.7 (74, 82.7) 76.2 (70.4, 81.1) 84.9 (76.1, 90.6)
1 year 66.5 (61.2, 71.2) 63.5 (57.2, 69.2) 73.7 (63.9, 81.3)
5 years 61.2 (55.9, 66.2) 58.6 (52.2, 64.5) 67.7 (57.5, 75.9)
10 years 56.2 (50.6, 61.4) 54.6 (48.1, 60.7) 59.2 (47.5, 69.2)
15 years 34.4 (25.8, 43.1) 32.6 (23.5, 42.0) 40.3 (19.6, 60.2)
HLHS, Hypoplastic Left Heart Syndrome.
residing in the most deprived areas (IMD quintile 5: n = 28,
31.4%) (Table 1). These cases most commonly occurred with
ventricular septal defect (n = 29), AVSD (n = 17), DORV
(n = 13), interrupted aortic arch (n = 10), and transposition
of the great vessels (n = 8), with 41 cases having “other” or
“unspecified” CHD.
Survival and Trends in Survival
Kaplan-Meier survival estimates for cases of HLHS born between
1998 and 2012 are shown in Table 2, with 84.4% of cases
surviving the first week of life, 76.2% the first month, 63.5% to
age 1 year, 58.6% to age 5 years, 54.6% to age 10 years, and 32.6%
to age 15 years. Compared to cases born 1998–2005, survival of
cases born 2006–2012 appeared to be slightly increased up to age
5 years (Figure 2), but similar thereafter. Due to violation of the
proportional hazards assumption, survival in the two era’s was
not formally compared.
The Kaplan-Meier survival estimates for cases of hypoplastic
left ventricle with additional CHD were slightly higher compared
to cases of HLHS, with 90.9% of cases surviving the first week of
life, 84.9% the first month, 73.7% to age 1 year, 67.7% to age 5
years, 59.2% to age 10 years, and 40.3% to age 15 years. However,
the difference in survival between the two phenotypes was not
statistically significant (log-rank test: p = 0.14). The association
between year of birth and mortality among cases of hypoplastic
left ventricle with additional CHD did not reach statistical
significance (log-rank test: p = 0.09), survival appeared to be
increased in those born 1998–2005 vs. 2006–2012 (Figure 2).
The survival rates at ages 1 month and 1 year for cases of
HLHS and hypoplastic left heart variant were significantly lower
than those of the general population of England and Wales (99.5
and 99.7%, respectively, test of proportions: p < 0.001).
Predictors of Survival
In all cases combined, there were significant associations between
mortality and gestational age at delivery (p= 0.007), birth weight
(p= 0.005), and infant sex (p= 0.01) (Table 3). One year survival
estimates increased with increasing gestational age at delivery
(52.0, 67.5, and 91.7% for preterm, term and post-term births),
although the association was only statistically significant in
preterm vs. term births (HR= 1.77, 95% CI: 1.21, 2.57). One year
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FIGURE 2 | Kaplan-Meier survival curves by year of birth.
survival estimates increased with increasing birth weight (57.1,
66.7, and 81.3% for low, average, and high birth weight), with the
association being statistically significant in low vs. average birth
weight cases (HR= 1.51, 95% CI: 1.09, 2.23) and high vs. average
birth weight (HR= 0.50, 95%CI: 0.25, 0.98).Males had decreased
risk of mortality compared to females (HR = 0.67, 95% CI: 0.50,
0.91). There was no evidence of an association between mortality
and plurality (p = 0.82), maternal age (p = 0.17), socioeconomic
deprivation (p= 0.65) or ECAs (p= 0.86).
DISCUSSION
Summary
Based on this population-based study of 343 traced cases of
HLHS or hypoplastic left ventricle with additional CHD born in
England and Wales, we have shown that survival to age 5 years
in the twenty first century is as high as 59 and 68%, respectively.
Survival was slightly greater amongst cases with hypoplastic left
ventricle with major CHD compared to HLHS, although the
difference was not statistically significant. This study shows that
the greatest risk of mortality in those with HLHS or hypoplastic
left ventricle and additional CHD occurs during the first week of
life, although survival continued to decrease over the 15 years of
follow-up. Survival estimates were increased in the later cohort
(2006–2012 vs. 1998–2005) although for cases of HLHS they may
only have been increased until age 5 years.
Strengths
The main strength of this study is the use of high-quality data
derived from four regional population-based congenital anomaly
registers. The registers were notified of cases from multiple
sources including prenatal ultrasound, cardiology databases,
cytogenetics and post-mortems. As a result, there is likely very
high ascertainment of cases. The ascertainment of cases at birth
as opposed to at surgical intervention is a further strength as this
has enabled pre-operative mortalities to be captured. However,
this also means that we have included in our estimates those that
opted for palliative care, which will have deflated the survival
estimates. A recent survey of European surgeons reported that
parental intention to treat was 95% in the UK, with the remaining
5% opting for comfort care (22). According to a US study of
military personnel, the proportion of parents opting for comfort
care is minimal (3%) since the 2000’s and so these cases probably
make up a very small proportion of our cohort (23).
A further strength of this study is that we attempted to
separate cases of HLHS and cases of hypoplastic left ventricle
with additional CHD subtypes such as DORV or AVSD. We
have shown that survival estimates may vary between these two
types of cases, with cases of hypoplastic left heart occurring
with additional CHD having slightly improved prognosis when
compared to classic cases of HLHS. Combining these cases may
also over inflate the survival estimate associated with classic
HLHS. Ideally, cases of HLHS would be coded as those that
underwent a Norwood stage I procedure only, but unfortunately
the data we used was not linked to information on surgical
intervention. As a result we may have misclassified some cases
of CHDwith hypoplastic left ventricle as HLHS. Additionally, we
may have misclassified cases that occurred with ventricular septal
defects as we were not able to identify the specific phenotype.
Where muscular VSD could occur as part of HLHS, the same
cannot be said for conotruncal VSD. However, misclassification
likely accounted for only minority of cases of VSD. However,
our approach allows cases with HLHS that did not survive until
Norwood stage I to be included in the analysis.
Limitations
This study has some limitations. Firstly, “fuzzy matching” was
used to link the congenital anomaly register data to death
registrations. As a result, we were not able to trace the survival
status of 28 cases. This could have caused bias in our survival
estimates if the survival statuses of these cases were significantly
different to the cases that were traced. These cases were slightly
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TABLE 3 | Risk factors for mortality in cases of HLHS or hypoplastic left ventricle with additional CHD born 1998–2012.
Risk factors N (%) Age 1 year
Kaplan-Meier
survival estimate
Hazard ratio (95% CI) P-value
Gestational age 0.007
Preterm (<37 weeks) 50 (14.5) 52.0 (37.4, 64.7) 1.77 (1.21, 2.57)
Term (37–41 weeks) 270 (78.3) 67.5 (61.6 (72.8) 1 (reference category)
Post-term (≥42 weeks) 12 (3.5) 91.7 (53.9, 98.8) 0.72 (0.29, 1.76)
Missing 13 (3.8)
Birth weight 0.005
Low (<2,500 g) 63 (18.3) 57.1 (44.0, 68.3) 1.51 (1.09, 2.23)
Average (2,500–3,999 g) 240 (70.1) 66.7 (60.3, 72.2) 1 (reference category)
High (≥4,000 g) 32 (9.3) 81.3 (63.0, 91.1) 0.50 (0.25, 0.98)
Missing 8 (2.3)
Maternal age 0.17
<20 44 (13.0) 54.6 (8.8, 67.8) 1.42 (0.92, 2.19)
20–34 225 (65.5) 68.9 (62.4, 74.5) 1 (reference category)
≥35 61 (17.7) 63.9 (50.6, 74.6) 1.31 (0.88, 1.93)
Missing 13 (3.8)
Sex
Female 139 (40.3) 59.7 (51.1, 67.3) 1 (reference category) 0.01
Male 204 (59.7) 71.1 (64.3, 76.8) 0.67 (0.50, 0.91)
Socioeconomic deprivation (IMD) 0.65
Least deprived Q1 38 (11.0) 73.7 (56.6, 94.9) 1 (reference category)
Q2 38 (11.3) 55.3 (38.3, 69.3) 1.57 (82.9, 2.97)
Q3 43 (12.5) 69.8 (53.7, 81.2) 1.06 (54.9, 2.04)
Q4 61 (17.7) 67.2 (53.9, 77.5) 1.18 (0.65, 2.17)
Most deprived Q5 93 (27.0) 67.4 (56.8, 76.0) 1.20 (0.68, 2.12)
Missing 71 (20.6)
Plurality 0.82
Singleton 320 (93.3) 66.3 (60.8, 71.1) 1 (reference category)
Multiple 15 (4.3) 66.7 (37.5, 84.6) 1.09 (0.51, 2.33)
Missing 8 (2.0)
Extra-cardiac anomalies 0.86
Isolated 297 (86.7) 67.3 (61.7, 72.4) 1 (reference category)
Structural ECA 27 (7.9) 55.6 (35.2, 71.8) 1.25 (0.72, 2.17)
Chromosomal ECA 19 (5.5) 68.4 (42.8, 84.4) 1.23 (0.67, 2.27)
HLHS, Hypoplastic Left Heart Syndrome, ECA, Extra-Cardiac Anomaly, IMD, Index of Multiple Deprivation.
more likely to be of low or high birth weight compared to the
traced cohort and were more likely to have been born earlier
in the study period, which suggests they might have had poorer
survival than the traced cases. Given that 93% of the cohort
were traced, the impact of any biases caused by excluding the
untraced cases will be minimal. Future linkage studies will benefit
by linking using National Health Service (NHS) number, which
is now routinely recorded by the NCARDRS. An additional
weakness was that our analysis of socioeconomic status (IMD)
was restricted to cases born to mothers resident in England
only, which reduced the power of this analysis. Moreover, due
to the low prevalence of hypoplastic left ventricle with additional
CHD, we may not have had adequate power to detect statistically
significant differences in survival between the two time periods
and when comparing to HLHS survival.
The BINOCARD did not routinely link to hospital episode
statistics, so we were not able to present pre- or post-operative
survival estimates relating to cardiac surgeries. Post-operative
survival estimates for cases treated in the UK are available via
NICOR, with 30 day post-operative survival for the Norwood,
Glenn and Fontan procedures exceeding 90% (9). There is very
limited information on modern pre-operative mortality rates,
with the most recent UK study of cases born between 1992
and 1993 reporting that 32% of cases died with no intervention
(12). However, it is not clear what proportion of these had an
intention to treat. Moreover, we could not attribute mortalities to
heart transplants which may have occurred at various points of
the life course and likely represent post-neonatal deaths. While
paediatric heart transplants are rare in the UK in general (n =
23 in 2012, according to the UK National Transplant Registry),
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the proportion of heart transplants for CHD doubled in the UK
between 2002 and 2012 (24). The proportion of HLHS cases that
result in transplant in the UK have not been recently reported,
but according to the Children’s Heart Federation are likely to
account for a very small number of cases due to the availability
of donor hearts within that age range (25). Linkage between the
data recorded by the congenital anomaly registers and hospital
episode statistics is now theoretically possible via the NCARDRS
and is currently being explored by the authors. The estimates in
this study could be used in conjunction with surgical survival
rates now provided by the National CHD audit to build a more
accurate picture of HLHS prognosis (9).
We found improved survival among cases of hypoplastic left
ventricle with additional CHD compared to HLHS. However,
this group represents a variety of different phenotypes which
may have variable prognoses. Further research into the specific
combinations of CHD subtypes is required to provide more
specific survival estimates for these cases.
The BINOCARD recorded routinely collected demographic
information for each case, but did not hold clinical information
on treatments or interventions. Due to the small number of
available demographic risk factors, the lack of clinical predictors
and the relative rarity of some of the characteristics (e.g., post-
term birth and high birthweight), we did not attempt to perform
amultivariable analyses or examine causality. Mediation analyses
could be performed to examine whether the negative impact
of low birth weight is accounted for primarily by the effects
of preterm birth. In future studies, a path analysis may be
applied to examine the complexity of the association between
socioeconomic deprivation and mortality, although we found
little evidence of an association in the univariable setting.
Comparison to Previous Studies
A previous UK study reported age 12 survival to be 21% for
cases born during 1992–1993 (12), which is consistent with cases
born in the early part of our study period. More recently, 5 year
survival for cases of HLHS born in 2000–2015 was 56.3% in the
UK, which is comparable to the 5 year survival reported in our
study (58.6%) (13). According to the UK National CHD audit
of surgeries performed between 2015 and 2016, 30 day post-
operative survival was 92.8% following the Norwood procedure,
98.2% following Glenn procedure and 99.6% following Fontan
(9). This suggests the greatest risk of mortality is associated with
the stage 1 repair, which usually occurs in the first 1 or 2 weeks
of life (8). This is reflected in our study which shows the highest
decrease in survival during the first week and between the first
week and first month of life. However, this high hazard rate may
also represent cases that died pre-operatively or those that opted
not to treat.
The survival estimates provided in this study relate to children
born in England and Wales, who were entitled to free health
care provided by the NHS. Our survival estimates may not be
representative of other populations with different health care
systems, for example in the USA where the health care system
is not publicly funded, and CHD outcomes vary according
to health insurance status (26). Perhaps for this reason, our
survival estimates exceed those of 60 cases born in Atlanta
(USA) between 1999 and 2005 (27), who had 10 year survival of
42.5% compared to our estimates of 54.7% (HLHS) and 48.0%
hypoplastic left ventricle with additional CHD between 1998 and
2005. Differences in survival may also be due to differences in
infant transplant provision, which is relatively uncommon in
the UK but may remain as a parental choice in some centres
in the USA (28). Conversely, in Denmark, which has a publicly
funded health care system, 10 year survival for 143 children
born with univentricular hearts between 2003 and 2015 exceeded
our survival estimates at 72%, although cases were ascertained
based on surgical procedures so some pre-operative mortalities
may not have been ascertained (29). A different regional study
in Denmark that ascertained 308 cases from a CHD register
reported much lower 5 year survival estimate of 18.8% for
cases of univentricular heart born between 2000 and 2009 (14).
These differences in survival estimates may also be related to the
definition of HLHS and the accuracy of coding, the decision to
terminate following a prenatal diagnosis or to opt for comfort
care, which vary by country and centre (22). In New Zealand,
5 year survival for cases of HLHS born between 2006 and 2010
was 62.1% although this estimate is based on 29 cases ascertained
on surgical procedures (15). The applicability of our survival
estimates to cases born in developing countries, where there is a
paucity of population-based research into HLHS survival, is also
not clear.
We found that preterm birth and low birth weight were
associated with an increased risk of mortality, which is consistent
with previous research (14, 27, 30). These factors may influence
the age at which surgeries are performed, the stability at
the time of operation, lung development and the technical
aspects of surgical reconstruction, which can negatively impact
on survival (31). Similar to previous studies, we also found
no evidence that ECAs increase the risk of mortality (27).
While this is not the case for most other CHD subtypes
(32), HLHS is perhaps so clinically severe that additional
congenital anomalies are overpowered in terms of mortality.
In cohorts from Denmark and the USA, increased mortality
rates among those with high vs. low levels of neighbourhood
poverty has been reported (14, 27, 30). We did not find any
statistically significant evidence of an association with IMD,
which could perhaps be reflective of the differences in our
health care systems. We found no association between mortality
and plurality or maternal age with is consistent with several
previous studies, although none of these are based on UK
populations (14, 27, 30).
In our study, female sex was associated with an increased
risk of mortality, possibly because these cases were more likely
to be HLHS as opposed to hypoplastic left ventricle with
additional CHD. Three population-based studies did not report
a significant association between infant sex and mortality (14,
27, 30), although in two the mortality rate among females
was greater (14, 27). In a USA based study, surgical mortality
was significantly greater in females following the Norwood
procedure, but not following the Glenn or Fontan procedures
(33). Another US study also reported an increased risk of
mortality in females following the Norwood procedure, although
this was of borderline statistical significance (15.5% in males vs.
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30.0% in females, p = 0.07) (34). Speculatively, females with
HLHS could have increased likelihood of being born with a
more severe HLHS phenotype, which would increase the gender
disparity in mortality, but there is no research to corroborate
this currently.
Implications
We have shown survival up to age 15 for those born with HLHS
has improved compared to previous studies based on earlier
cohorts. This information is important for counselling parents
when their child is diagnosed with HLHS. However, the survival
estimates reported in this study need to be considered alongside
data on quality of life and morbidity. There is some evidence that
children with HLHS experience lower quality of life, increased
risk of neurodevelopmental delay, behavioural problems and
decreased functional status (35, 36). Given that survival was
very rare until the 1990s and 2000s, there is also a paucity of
information known on longer term survival and quality of life
in adults living with palliated HLHS.
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